Apimeds Pharmaceuticals US Inc APUS Stock Analysis
- NYSE American
- Stock
- Market open · no trades yet today
$2.73 down $0.19, 6.51% at close Nov 5
Last close · Previous close $2.92
- Market cap
- $4.12MAt the Nov 5 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$2.73down $0.19, 6.51%Thu, Nov 5 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$2.92Nov 4
- Volume64.75KNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume353.54KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $1.51 to $59.70; now $2.73
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 5 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
APUS trailed the S&P 500 in all 4 periods.
| Period | APUS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | APUS: down 40.5% S&P 500: down 5.4% | APUS trailed the S&P 500 by 35.1 percentage points Trailed |
| 3M | APUS: down 41.3% S&P 500: down 4.5% | APUS trailed the S&P 500 by 36.8 percentage points Trailed |
| YTD | APUS: down 83.4% S&P 500: up 8.3% | APUS trailed the S&P 500 by 91.7 percentage points Trailed |
| 1Y | APUS: down 90.0% S&P 500: up 9.3% | APUS trailed the S&P 500 by 99.3 percentage points Trailed |
$10,000 invested in APUS a year ago (Nov 5, 2025) would be worth about $996 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $10,934.
APUS trailed the S&P 500 in all 4 periods.
| Period | APUS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | APUS: down 40.5% S&P 500: down 5.4% | APUS trailed the S&P 500 by 35.1 percentage points Trailed |
| 3M | APUS: down 41.3% S&P 500: down 4.8% | APUS trailed the S&P 500 by 36.5 percentage points Trailed |
| YTD | APUS: down 83.4% S&P 500: up 7.5% | APUS trailed the S&P 500 by 90.9 percentage points Trailed |
| 1Y | APUS: down 90.0% S&P 500: up 8.2% | APUS trailed the S&P 500 by 98.2 percentage points Trailed |
$10,000 invested in APUS a year ago (Nov 5, 2025) would be worth about $996 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $10,818.
All-time high
$38.95
Closing high on . Now 93.0% below that record.
Split-adjusted daily closes since May 9, 2025.
Stock splits
1
1-for-10 on . Share counts adjust after each split.
Valuation
The Nov 5 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
Other valuation measures
- Price-to-bookPausedBook value as of Jun 30, 2026
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - −324.06%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $10.42MAt the Nov 5 close
What it would cost to buy the whole business: the market cap at the Nov 5 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own APUS DCF in Excel. Value Apimeds Pharmaceuticals US with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$58.17M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$332.52K | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$311.63K | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$402.40K | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$2.66M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$1.78M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$1.16M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$35.06M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$20.17M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY22 (Dec 31, 2022) | $0.00 | −$668.67K | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $0.00 | −$777.69K | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $0.00 | −$1.39M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $0.00 | −$6.00M | Paused See the note under the price. |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$13.35MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$13.28MLast 12 months
- Capital spending$71.72KLast 12 months
Shareholder returns
- $323.32KLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$323.32KLast 12 months
Balance sheet
- $125.02MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$14.58MAs of Jun 30, 2026
- Net cash$110.44MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 0.51As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.14As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −59.0%Last 12 months
Over the last 12 months, Apimeds Pharmaceuticals US lost money: its net loss was 59.0% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −52.6%Last 12 months
Over the last 12 months, Apimeds Pharmaceuticals US’s net loss was 52.6% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Apimeds Pharmaceuticals US Inc
Apimeds Pharmaceuticals US Inc
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- New Jersey, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- NYSE American
- Asset type
- Common stock
- Price history since
APUS news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
APUS stock FAQ
What is APUS stock’s price today?
Apimeds Pharmaceuticals US (APUS) traded at $2.73 at the close on , down $0.19 (6.51%) from the previous close of $2.92. Over the past 52 weeks it has traded between $1.51 and $59.70.
What is Apimeds Pharmaceuticals US’s market cap?
Apimeds Pharmaceuticals US’s market capitalization is about $4.1 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $2.73 (how market cap works).
Does APUS pay a dividend?
Apimeds Pharmaceuticals US hasn’t paid a dividend in the last twelve months.
What is APUS’s 52-week high and low?
Over the past 52 weeks APUS has traded as low as $1.51 and as high as $59.70. At $2.73 at the close on , it is 95.4% below that high and 80.8% above the low.
What is APUS’s all-time high?
APUS’s highest closing price was $38.95 on , adjusted for stock splits. At $2.73 at the close on , it is 93.0% below that record.
Has APUS stock ever split?
Yes, once: 1-for-10 on .
How has APUS stock performed?
Including dividends and measured to the close on , APUS has returned −83.4% so far this year and −90.0% over the past year. Over the same periods the S&P 500, measured by SPY, returned +8.3% and +9.3%. Past performance doesn’t predict future returns.
What sector and industry is Apimeds Pharmaceuticals US in?
Apimeds Pharmaceuticals US is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is headquartered in New Jersey, USA.
What exchange does APUS trade on?
Apimeds Pharmaceuticals US trades on the NYSE American under the ticker symbol APUS. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.